Research programme: protein therapeutics - Eli Lilly/Xencor
Latest Information Update: 29 Apr 2008
At a glance
- Originator Eli Lilly; Xencor
- Class Proteins
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 29 Apr 2008 This collaboration is still active
- 18 Apr 2005 Xencor has announced that Eli Lilly has exercised its option to develop a therapeutic protein created by Xencor
- 27 Feb 2004 Preclinical trials in Undefined in USA (unspecified route)